MARKET

BFRIW

BFRIW

Biofrontera
NASDAQ
0.0700
0.0000
0.00%
Closed 09:30 12/29 EST
OPEN
--
PREV CLOSE
0.0700
HIGH
--
LOW
--
VOLUME
17
TURNOVER
--
52 WEEK HIGH
0.2770
52 WEEK LOW
0.0251
MARKET CAP
--
P/E (TTM)
-0.0380
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BFRIW last week (1222-1226)?
Weekly Report · 14h ago
Weekly Report: what happened at BFRIW last week (1215-1219)?
Weekly Report · 12/22 09:44
Biofrontera Inc. Secures Full Rights to Ameluz and RhodoLED Portfolio
Reuters · 12/18 13:45
BIOFRONTERA INC. COMPLETES TRANSFER OF AMELUZ® AND RHODOLED® FDA APPROVAL AND ASSOCIATED INTELLECTUAL PROPERTY PORTFOLIO
Reuters · 12/18 13:45
Weekly Report: what happened at BFRIW last week (1208-1212)?
Weekly Report · 12/15 09:48
Weekly Report: what happened at BFRIW last week (1201-1205)?
Weekly Report · 12/08 09:48
BIOFRONTERA INC. ANNOUNCES FILING OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA (SBCC) WITH AMELUZ®-PDT
Reuters · 12/02 13:45
BIOFRONTERA: FILING SEEKS TO EXPAND AMELUZ LABEL TO INCLUDE TREATMENT OF SBCC TREATMENT WITH PDT USING ITS BF-RHODOLED OR RHODOLED XL RED LIGHT LAMPS
Reuters · 12/02 13:45
More
About BFRIW
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Webull offers Biofrontera Inc stock information, including NASDAQ: BFRIW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRIW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BFRIW stock methods without spending real money on the virtual paper trading platform.